BPC-157 vs TB-500: Evidence, Legal Status and Differences

By Editorial team. Updated Oct 15, 2026. Awaiting expert review

BPC-157 and TB-500 are two different peptides that are often marketed for similar purposes and sold side by side, sometimes premixed in one vial [4, 5]. BPC-157 is a synthetic 15-amino-acid peptide based on a sequence from gastric juice [1]. TB-500 is understood to be a seven-amino-acid fragment of a different natural protein, thymosin beta-4 [5, 6]. Neither is an approved medicine, and for both, almost all of the evidence comes from animal and cell studies [2, 10].

What each one is

BPC-157 (“body protection compound 157”) is a synthetic pentadecapeptide, a chain of 15 amino acids, whose sequence was originally isolated from gastric juice [1]. It has no United States Adopted Name and is not a component of any FDA-approved drug [4].

TB-500 is the name used for products that FDA understands to contain a synthetic seven-amino-acid fragment of thymosin beta-4 (Tβ4) [5]. Tβ4 itself is a naturally occurring peptide of 43 amino acids [6]. When anti-doping chemists analyzed a product sold as TB-500, they identified the acetylated 17–23 fragment of Tβ4, Ac-LKKTETQ [7]. So “TB-500” and “thymosin beta-4” are different molecules, even though they are often discussed as if they were the same [7, 5].

How the evidence compares

For BPC-157, a 2025 systematic review of the orthopedic literature included 36 studies: 35 were preclinical, one was clinical, and the authors found no clinical safety data [2]. A separate 2025 review counted three small human pilot studies, in knee pain, interstitial cystitis and an intravenous safety study, and concluded that rigorous, large-scale trials are lacking [1]. FDA’s 2026 review found five small, short human studies in all, adding one in healthy volunteers and one in people with ulcerative colitis [4]. An earlier review noted that most studies used small rodent models and that only a handful of research groups had studied the peptide in depth [3].

For TB-500, the gap is wider. FDA has not identified any human exposure data for the fragment [9]. Most published research concerns full-length Tβ4, which sped up healing in animal wound models and was tested in small phase 2 trials in pressure ulcers, venous ulcers and epidermolysis bullosa wounds [8, 6]. Because the fragment and the full-length protein are different molecules [7, 5], those trials don’t show what TB-500 itself does. A 2026 primer for sports-medicine physicians found that Tβ4 and TB-500 promoted blood-vessel growth and tissue repair in preclinical models, but that human orthopedic data are lacking [10].

A 2026 review of peptides sold directly to patients, which covered both compounds, concluded that rigorous human safety data are scarce for unapproved peptides like these [11].

Regulation and sport

Neither compound is an approved medicine in the markets in the table above. FDA’s compounding advisory committee reviewed both in July 2026, but its vote is not binding and FDA has not added either to its list of substances pharmacies may compound with [12, 15]; WADA prohibits both at all times [13].

Quality risks when buying

Products sold for “research use” are made and sold largely outside drug regulation [11, 2]. FDA says it has encountered multiple salts and derivatives sold under each name [4, 5], and its safety review flagged possible immune reactions (immunogenicity) and peptide-related impurities for both [9]. For BPC-157, FDA treats the free base and the acetate salt as distinct substances, so a certificate of analysis (COA) should say which form was tested [4]. For TB-500, the COA should state the exact sequence and molecular mass, because the fragment and full-length Tβ4 are not interchangeable [7]. Thymosin beta-4 was also among the black-market products analyzed by the Cologne anti-doping laboratory in Germany between 2010 and 2013 [14].

A vial that combines both peptides is harder to check: its report should measure each peptide separately. Our guides explain how to read a peptide COA, how to check a peptide vendor and what “research use only” means.

More on each

The BPC-157 overview and the TB-500 overview go into each compound’s sources in more depth. We track current listings on the BPC-157 price page and the TB-500 price page, and premixed vials separately on the BPC-157 and TB-500 blend page.